A PHASE 1 STUDY OF RETIFANLIMAB (INCMGA00012), A PD-1 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS IN RECURRENT MSI-HIGH OR DMMR ENDOMETRIAL CANCER (POD1UM-101)

被引：4

作者：

Berton-Rigaud, Dominique ^{[1
]}

Vergote, Ignace ^{[2
]}

Pautier, Patricia ^{[3
]}

Kryzhanivska, Anna ^{[4
]}

Angelergues, Antoine ^{[5
]}

Kornacki, Deanna ^{[6
]}

Dudzisz-Sledz, Monika ^{[7
,8
]}

Tian, Chuan ^{[6
]}

Bourayou, Nawel ^{[6
]}

Selle, Frederic ^{[5
]}

机构：

[1] Inst Cancerol Ouest, St Herblain, France

[2] UZ Leuven, Leuven, Belgium

[3] Gustave Roussy, Villejuif, France

[4] Reg Clin Oncol Ctr, Ivano Frankivsk, Ukraine

[5] Grp Hosp Diaconesses Croix St Simon, Paris, France

[6] Incyte Corp, Wilmington, DE USA

[7] KCR SA, Warsaw, Poland

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

来源：

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0268

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

268

引用

页码：A164 / A165

页数：2